Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Abuse, Drug: early-phase trial registry

3 of 5 indexed Abuse, Drug trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 3 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Abuse, Drug: 5 US clinical trials tracked, 3 recruiting.

Abuse, Drug is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is University of California, Los Angeles, running 5 of these trials.

Enrollment posture brief

Registry condition abuse-drug

OPEN 3 | RECR 60% | LATE 0 | EARLY 5 | RANK #3391 | SPON 5

Nearest open-share peer: Acute Kidney Injury (AKI) (60% recruiting · 5 trials)

Ablation80%ACL Reconstruction80%Acceptability60%Abuse, Drug (this)60%Acral Lentiginous Melanoma20%
Open-enrollment share among volume-matched conditions near Abuse, Drug

Abuse, Drug lists 3 open slots (60% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Abuse, Drug on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Abuse, Drug is recruiting above its size-band peers.

    3 of 5 indexed trials (60%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Abuse, Drug research.

    University of California, Los Angeles accounts for 5 of 5 trials (100%). 1 distinct sponsors appear on at least one study for this condition label.

  3. Most Abuse, Drug trials plan to enrol fewer than 100 people.

    Median target enrolment is 45 among the 5 trials that report a genuine target (sentinel values excluded). 3 of those (60%) plan for fewer than 100 participants.

  4. Abuse, Drug research is mostly interventional.

    5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 15

Phase Distribution

PhaseTrial count
Phase 1 5

Named interventions

Most-linked intervention names on Abuse, Drug records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

High THC Drug
2 trials
Low THC Drug
2 trials
Placebo Drug
2 trials
High CBG Drug
1 trials
Low CBG Drug
1 trials
Low Beta-Caryophyllene Drug
1 trials
High Myrcene Drug
1 trials
Low Myrcene Drug
1 trials

US sites by state

Facility locations filed on Abuse, Drug trials. A trial with sites in several states counts in each.

California 5 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Abuse, Drug page

5 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Abuse, Drug condition card totals 5 registered trials; most-linked intervention High THC; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.